Kornimate/medical-research-clean huggingface dataset:
effect of egf with silver sulfadiazine cream compared with silver zinc sulfadiazine cream for treatment of burn wound

Conditions: Deep Partial Thickness Burn

Summary: partial thickness burn wounds are most likely to heal within 2-3 weeks mainly by mechanism of epithelialization. however, it depends on the depth of the wounds and patient condition. infection is one of the most common complications causing delay in wound healing which might affect to quality of patient's life. generally, the standard treatment of partial thickness burn wound is topical 1% silver sulfadiazine cream. previous studies had been reported the broad spectrum antimicrobial activity of silver sulfadiazine cream but it did not demonstrate the accelerating effect of wound healing. therefore, the combination of substance which can promote wound healing to topical silver sulfadiazine cream might benefit for partial thickness burn wound treatment. the objective of this study was to compare the results of partial thickness burn wound treatment at burn unit, siriraj hospital with topical cream containing 1% silver sulfadiazine plus 6% epidermal growth factor (egf) and 1% silver zinc sulfadiazine. the demographic data (age, sex, %body surface area burn), time of wound closure, pain and itching, dose and type of pain and itching medication, adverse effect of topical medication, some laboratory results and cost of expenses. this is the prospective, double blinded, randomize-controlled study. the sample sizes were partial thickness burn wound patients who were treated at burn unit, siriraj hospital. patients were allocated into 2 groups receiving treatment with either topical silver sulfadiazine plus egf or silver zinc sulfadiazine. all parameter data were analyzed with repeated measure anova and independent t-test.


Eligibility criteria:
inclusion criteria: * aged 18-60 years. * partial thickness burn wound more than 20%tbsa. * no underlying diseases that interfere wound healing such as chronic kidney disease, diabetes mellitus, liver disease, immunocompromised deficiency. * in case of reproductive age woman, they have to control the birth rate at least 4 weeks before study. * patients who are willing to participate in the trial and to sign the informed consent form. exclusion criteria: * immunocompromised defects * known allergy or hypersensitivity reaction to epidermal growth factor, silver sulfadiazine or other substances in formulation. * pregnancy or lactation

Keywords: wound healing epithelialization safety
an observational study to evaluate safety and efficacy of remsima™ in patients with ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: an observational, prospective cohort study to evaluate safety and efficacy of remsimatm in patients with ankylosing spondylitis

this is a longitudinal, observational, prospective cohort study to assess the safety and efficacy of remsimatm in patients with as in comparison with patients receiving other tnf blockers. for the remsimatm cohort data will be collected for patients who commence treatment with remsimatm in accordance with the product label at the time of enrolment. patients who have been treated with remicade® prior to enrolment, their dosing schedule will be continued appropriately. this observational study allows drug switching between anti-tnf drugs. if switched to remsimatm, data will be collected until the end of study for each patient. if switched to other anti-tnf drugs (infliximab (remicade®), etanercept, adalimumab and etc.), data will be collected until 1 year from the day of switch or until the end of study for each patient, whichever reaches earlier. for switched patients, their assessment schedule will be re-started from the day of switch. patients will undergo safety and efficacy assessments in accordance with routine medical practice. the decision to treat with remsimatm will be independent of the decision to enroll the patient in this registry.

Eligibility criteria:
inclusion criteria: * adult patients * patients with active as * patients who meet the following conditions can be enrolled: i) the remsimatm cohort will include all patients who will start remsimatm at the time of enrolment in accordance to the approved product label ii) patients who have started to be treated with an established anti -tnf such as infliximab (remicade®), etanercept, adalimumab and etc. within 6 months * female patients of childbearing potential who agree to use of adequate contraception to prevent pregnancy and continuation of contraceptive use for at least 6 months after their final dose of remsimatm. * patients (or legal guardian, if applicable) who are willing to give informed consent for long term follow-up including access to all medical records exclusion criteria: * patients with a history of hypersensitivity to infliximab * patients with a current or past history of chronic infection * current diagnosis of tb or severe or chronic infections (e.g. sepsis, abscess or opportunistic infections or invasive fungal infections), or a past diagnosis of tb or severe or chronic infection, without sufficient documentation of complete resolution following treatment. * recent exposure to persons with active tb, or a positive test result for latent tb (defined as a positive interferon-γ release assay \[igra\] with a negative examination of chest x-ray) at screening. * patients with moderate or severe heart failure (nyha class iii/iv).
behavior during and after covid-19 crisis

Conditions: Exercise; Nutritional Status; Sleep

Summary: a crisis situation leads to changes in life. during december 2019, many people contracted pneumonia in the chinese city of wuhan. on january 7, 2020, the novel coronavirus (covid-19) was identified as the cause of this disease. within five months, the virus spread around the globe and forced countries to restrict public life. due to the high infection rates in europe, a lockdown followed between march and april 2020 (except in sweden). as the number of infections decreased, european countries began to gradually relax the lockdown from may 2020. the lockdown and the later stages of loosening have an impact on lifestyle. institutions of higher education must also adapt to this situation and have switched to distance learning. the university of applied sciences of bern (bfh), department of health professions with the departments (dhp) of nutrition and dietetics and physiotherapy, considers the question of the degree to which nutritional and exercise behavior has changed. the findings provide recommendations for future crises for students and employees of the bfh-dhp. in order to achieve this, at the bfh-dhp two anonymous online surveys will be conducted.

there is little evidence of how physical activity and eating behavior changes during a pandemic period and in the period after a pandemic period of students and employees at the bfh-dhp. this observational study will assists to determine the impact of an immediate change within a pandemic on physical activity, nutrition, sleep and alcohol consumption and the consequences after a period of one year.

Eligibility criteria:
inclusion criteria: * students from the bern university of applied sciences, department of health professions * students from the bern university of applied sciences, department of health professions exclusion criteria: -
sbirt implementation for adolescents in urban federally qualified health centers

Conditions: Alcohol-induced Disorders; Drug Users; Tobacco Use Disorder

Summary: the purpose of this study is to examine the implementation of two evidence-based intervention strategies of sbirt (generalist vs. specialist) for adolescent alcohol, tobacco, other drug use, and hiv risk behaviors.

guided by proctor's conceptual model of implementation research, the proposed study is a multi-site, cluster randomized trial to compare two principal strategies of sbirt delivery within adolescent medicine. in the generalist strategy, the primary care provider delivers brief intervention (bi) for substance misuse. in the specialist strategy, bis are delivered by behavioral health counselors. the 7 study sites, primary care clinics operated by a large, urban federally qualified health center in baltimore, will be randomly assigned to implement sbirt for adolescents using either the generalist or specialist strategies. staff at each site will be trained in the assigned implementation strategy, and quarterly booster trainings will be provided during the implementation period. implementation outcomes, including: penetration, costs/cost-effectiveness, acceptability, timeliness, fidelity/adherence, and patient satisfaction will be assessed during the 18-month-long implementation period using a complementary combination of administrative service encounter data, provider and patient surveys, and qualitative interviews. at the end of the active implementation period, all training and technical support activities will cease for 12 months in order to measure relative sustainability. the study will also examine the effectiveness of integrating hiv risk screening within an sbirt model.

Eligibility criteria:
inclusion criteria: * clinic staff exclusion criteria: -

Keywords: implementation sbirt alcohol screening drug screening brief intervention referral to treatment adolescents federally qualified health centers
a study of tarceva (erlotinib) in combination with gemcitabine in unresectable and/or metastatic cancer of the pancreas: relationship between skin toxicity and survival

Conditions: Pancreatic Cancer

Summary: this single arm study will evaluate the relationship between the skin toxicity of tarceva in combination with gemcitabine, and survival, in patients with advanced and/or metastatic pancreatic cancer. all patients will receive gemcitabine 100mg/m2 i.v. weekly; tarceva will be administered 100mg po per day. the anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age; * locally advanced and/or metastatic pancreatic cancer (stage iii or iv); * karnofsky performance status of \>=60%. exclusion criteria: * local(stage ia to iib) pancreatic cancer; * \<=6 months since last adjuvant chemotherapy; * previous systemic therapy for metastatic pancreatic cancer; * other primary tumor within last 5 years (except for adequately treated cancer in situ of cervix, or basal cell skin cancer); * clinically significant cardiovascular disease.
investigating the feasibility and preliminary effects of yoga on excessive gestational weight gain

Conditions: Weight Gain

Summary: this study will test the feasibility (i.e., acceptability, demand) of a 12-week prenatal yoga intervention on excessive gestational weight gain (gwg) in pregnant women in the second trimester (enrolled at 12-24 weeks). participants will be randomized into the prenatal yoga intervention or a pregnancy education (e.g., information on preparing for motherhood, labor and delivery etc.) control group. participants in both groups will be asked to attend one 75 minute class per week. the investigators hypothesize that prenatal yoga intervention will be feasible for pregnant women. the study aims are as follows: primary aim: determine the feasibility (i.e., acceptability, demand) of a 12-week prenatal yoga intervention in pregnant women. in a randomized controlled pilot study comparing prenatal yoga to a pregnancy education control condition, the investigators will assess 1) acceptability (defined as satisfaction, intent to continue use, perceived appropriateness) and 2) demand (defined as attendance/adherence). exploratory aim 1: ascertain the preliminary effects of prenatal yoga on excessive gwg \[i.e., weight gain exceeding institute of medicine (iom) recommendations\]. the investigators will compare weight change between intervention and control groups. exploratory aim 2: explore the potential mediators (i.e., mindfulness, self-regulation) on the effect of prenatal yoga on excessive gwg.


Eligibility criteria:
inclusion criteria: * women 18-46 years of age (childbearing age) * primiparous (women giving birth for the first time) * 12-24 weeks gestation at onset of intervention * reside in the phoenix metropolitan area * singleton pregnancy * english speaking * not planning on moving before giving birth * can attend at least one session per week exclusion criteria: * current alcohol or substance abuse * engage in ≥150 min of physical activity * participation in ≥30 minutes/week of yoga or contemplative practice (i.e., meditation, qigong) for the previous six months * pre-pregnancy bmi ≥40 or \<18.5 * denial of physical activity participation from a physician (parmed-x for pregnancy)

Keywords: pregnancy prenatal yoga excessive gestational weight gain
study of nerve block anesthesia for surgery of hip fracture in the elderly

Conditions: Anesthesia; Reaction

Summary: the investigators aim to examine target-controlled propofol infusion as a technique of anesthesia for surgery of hip fracture under ultrasound guidance lumbar and sacral plexus block or lumbar, sacral and paravertebral nerve block in the elderly; and to evaluate which regional anesthesia was more sufficient for the old.

eighty patients with american society of anesthesiologists（asa） ⅰ-ⅲ older than 80 years are randomly assigned to 2 groups: a lumbar and sacral plexus block(ls) group with 20ml 0.5% ropivacaine at lumbar plexus(level l3-4) and 10ml 0.5%ropivacaine at sacral plexus; a lumbar, sacral plexus and paravertebral nerve block(lsp) group with 20ml 0.5% ropivacaine at lumbar plexus(level l3-4) , 10ml 0.5%ropivacaine at sacral plexus and 10ml 0.5%ropivacaine at paravertebral nerve(level l1). the target-controlled propofol infusion is started immediately after positioning the patient on the operating table. the initial target concentration was 0.5μg/ml. the infusion rate is adjusted every 5min by increasing or decreasing the target concentration by 0.2μg/ml steps based on the patients' respiratory rate(rr), blood pressure(bp), heart rate(hr), and level of sedation(score of 5 on ramsay sedation scale ). the minimal, maximal, optimal target concentration, cumulative propofol dose, frequency of spontaneous movement and incidences of associated complications are recorded. patients were phoned for followup and questioned for activity status in one year. if the patients were dead, date of death; if they survived, daily living activity questioned.

Eligibility criteria:
inclusion criteria: * asa ⅰ-ⅲ * hip fracture need surgery exclusion criteria: * patient refusal * chronic use of opioids * coagulation disorders * preexisting neurological disorders
organ protection with sevoflurane postconditioning

Conditions: Hepatectomy

Summary: organ protection, volatile anesthetics, postconditioning, hepatic surgery

this study aims at the evaluation of a potential attenuation of ischemic-reperfusion injury in the liver with sevoflurane postconditioning upon reperfusion.

Eligibility criteria:
inclusion criteria: * older than 18 years * patients undergoing liver resection (benign or malignant tumors) exclusion criteria: * non-german speakers * laparoscopic liver resection * coagulopathy (platelets \< 50'000/ml, quick \< 50%) * liver cirrhosis

Keywords: ischemia reperfusion injury organ protection
non-invasive ventilation versus high flow oxygen

Conditions: Pneumonia-associated Acute Hypoxemic Respiratory Failure

Summary: the purpose of the study is to compare the efficacy of alternating non invasive ventilation niv and high flow oxygen hfo compared to high flow oxygen hfo alone on gas exchanges and prognosis in pneumonia-associated acute hypoxemic respiratory failure

both non invasive ventilation (niv) and high flow oxygen through nasal cannula (hfo) are widely used in the setting of hypoxemic respiratory failure of heterogeneous etiology, with no definitive evidence for the superiority of one technique on the other. the purpose of this study is to determine whether alternating niv and hfo brings any advantage on gas exchanges and prognosis compared to the use of hfo alone in the homogeneous setting of pneumonia-associated acute hypoxemic respiratory failure

Eligibility criteria:
inclusion criteria: * diagnosis of pneumonia based on at least two clinical/laboratory criteria and 1 radiologic criterion among the following: * clinical criteria: fever, cough, purulent sputum, pulmonary examination positive for signs consistent with pneumonia * laboratory criteria: leukocytosis (white blood cells \>10000/mcl) or leukopenia (white blood cells \< 4000/mcl), rise of the inflammatory markers * radiologic criteria: consolidations at chest x-ray or ct scan * hypoxemic respiratory failure, based on all the following criteria * pao2/fio2 \< 300 after at least 15 minutes conventional oxygen therapy with a fio2 ≥ 50% * respiratory rate (rr) ≥ 25/min or need for use of accessory muscles * informed consent to study participation exclusion criteria: * age \< 18 years * hypercapnic respiratory failure (pco2 \> 60 mmhg at presentation) such as in chronic obstructive pulmonary disease * presence of another cause of hypoxemic respiratory failure - e.g. pulmonary embolism, acute respiratory distress syndrome (ards), pulmonary oedema * hemodynamic instability with necessity for use of inotropes and/or vasopressors * indication for endotracheal intubation (eti): glasgow coma scale (gcs) \<8, agitation, device intolerance, respiratory arrest * immunosuppression (chronic immunosuppressive therapy, clinical history positive for any immunodeficiency - congenital or acquired) * do not resuscitate (dnr) and do not intubate (dni) indication * tracheostomy * nocturnal cpap ventilation therapy * any other condition which the clinician would considered an adjunctive risk for taking part in the study or that would not permit the participant to complete it

Keywords: noninvasive ventilation high flow oxygen nasal cannula pneumonia acute hypoxemic respiratory failure
asphyxia associated metabolite biomarker investigation (aambi)

Conditions: Asphyxia Neonatorum

Summary: verification of biomarkers in a human population for their ability to diagnose the severity of neonatal asphyxia. these biomarkers linked to asphyxia have been identified in animal studies.

the aim of the study is to verify the application of combinations of several laboratory parameters in early postnatal blood samples, for identification of infants, who will suffer from early abnormal neonatal neurological outcome, in a population at risk. the population at risk is defined as term and late preterm (\>36 weeks of gestation) human infants following perinatal hypoxia-ischemia with or without postnatal resuscitation.

Eligibility criteria:
inclusion criteria: group 1: inclusion criteria fulfilled for hypothermia treatment group 2: infants with suspected perinatal brain injury due to one of the followings * perinatal hypoxia-ischemia (defined as a perinatal acidosis indicated by a ph≤7.10 or a base excess ≤-12mmol/l in umbilical cord blood or early postnatal blood collected at \<90min of age (outborn patients) * 5min apgar-score ≤ 5 * need for resuscitation after birth for \>1 min. after birth, positive pressure respiratory support with face mask or endotracheal tube, or cardiac compressions group 3: uaph \>7,25, and adaptation disorder of the newborn and need of postnatal clinical surveillance exclusion criteria: gestational age \< 36 weeks * age at time of screening \>2,5h * congenital malformation * missing or invalid informed parental consent * unsuccessful resuscitation * infant considered not-viable * decision for palliative care only

Keywords: biomarkers
metabolism and toxicity of acetaminophen

Conditions: Pain

Summary: the purpose of this study is to investigate how acetaminophen (apap) is released into the urine and blood; to determine how the blood levels of acetaminophen and its breakdown products affect the preterm infant's health; to decrease adverse drug reactions; and to collect data on how the genetic make-up or characteristics affect how apap is handled within the preterm infant. by taking several blood and urine samples during the study, we will be able to check the blood levels (called pharmacokinetics) of apap in preterm babies.

study procedures: the decision to replace standard intravenous morphine therapy with apap will be made by the attending neonatologist. length of participation: 60 hours. no patient will be prescribed the medication specifically for the study purposes in the study protocol.

Eligibility criteria:
inclusion criteria: * preterm and term neonates of both genders and all races * a postnatal age of less than 28 days * ga's of from 22 to less than 37 weeks * an indwelling (peripheral or umbilical) arterial line * a clinical indication for intravenous administration of pain relief medication exclusion criteria: * neonates with severe asphyxia * grade iii or iv intraventricular hemorrhage, major congenital malformations/facial malformations (e.g., cleft lip and palate), * neurological disorders * those receiving continuous or intermittent neuromuscular blockers * clinical or biochemical evidence of hepatic renal failure (including systemic hypoperfusion)

Keywords: acetaminophen preterm infants
evaluation of equine antibody treatment in patients with covid 19 infection

Conditions: SARS-CoV-2 Infection

Summary: this is a prospective, randomized, multi-center, open label, phase 1/2 study to evaluate the safety and efficacy of equine covid-19 antiserum \[f(ab')2\]. bsv has developed equine covid-19 antiserum from horse serum for the use in covid-19 infection. the indication proposed is to provide passive immunization to the covid-19 infected patient thereby reducing the viral load and prevention of disease progression. clinical phase 1 and phase 2 studies have been planned to be conducted. the phase 1 study will be conducted on two dosages to find the safety and tolerability in patients. based on the results of phase 1 study the phase 2 shall be initiated.


Eligibility criteria:
inclusion criteria: 1. age phase 1: ≥ 18 years to ≤ 55 years phase 2: ≥ 18 years to ≤ 65 years 2. are male or non-pregnant females who agree to contraceptive requirements. 3. patients with rt-pcr confirmed covid-19 in ≤ 72 hours prior to randomization \[ct ≥ 24\]. 4. have spo2\<94% (range 90-93%) on room air. 5. have one or more of the following- dyspnea, fever, cough, respiratory rate ≥ 24 per minute and heart rate up to 120 per minute. 6. patients who agree to participate in the study and follow all study related procedures exclusion criteria: 1. require mechanical ventilation 2. have oxygen saturation less than or equal to 89 percent 3. patients re-infected with sars-cov-2 4. suspected or proven serious active bacterial fungal viral or other infection 5. patients with positive skin test with ip 6. patients with known equine allergies or past medical history of serum sickness 7. patient who are hiv, hcv, hbsag positive or immunocompromised 8. patients with significant co-morbidities at screening 9. moribund state 10. pregnant or nursing women 11. participating in other clinical trial

Keywords: 2019 novel coronavirus disease covid19 coronavirus disease 2019
psycho-social aspects after a physiotherapy intervention in chronic tmd pain

Conditions: TMD

Summary: how patients psycho-social factors change after a physical intervention in patients with chronic tmd pain


Eligibility criteria:
inclusion criteria: * chronic myofascial tmd pain exclusion criteria: * neurologic pain